Última actualización 18 de agosto de 2026
Key finding
Total hypoglycemia rate was 38% less compared to Glibenclamide arm (p = 0.024).
Xiaoke Pill combined with glibenclamide in adults with type 2 diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
Xiaoke Pill combined with glibenclamide in adults with type 2 diabetes.
This study evaluated Xiaoke Pill combined with glibenclamide in adults with type 2 diabetes.
Limitations were not clearly described in the extracted text.
Published in
Publication details and source links for this paper.
Linong J, Xiaolin T, Hongyuan W, et al. Efficacy and Safety of Traditional Chinese Medicine Combined with Glibenclamide in Type 2 Diabetes: A Multicenter, Double-Blind, Non-Inferiority Trial. PLoS ONE. 2013;8(2):e56703. doi:10.1371/journal.pone.0056703
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Glibenclamide, Xiaoke Pill combined with Glibenclamide and Achievement of HbA1c ≤ 6.5%, HbA1c, Total hypoglycemia rate, and 1 more.
This study contributes evidence to
Primary intervention
Glibenclamide
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
7
Evidence pairs
514
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Glibenclamide → Achievement of HbA1c ≤ 6.5%
Glibenclamide → Achievement of HbA1c ≤ 6.5%
Glibenclamide → Total hypoglycemia rate
Glibenclamide → Total hypoglycemia rate
Xiaoke Pill combined with Glibenclamide → Achievement of HbA1c ≤ 6.5%
Xiaoke Pill combined with Glibenclamide → Achievement of HbA1c ≤ 6.5%
Xiaoke Pill combined with Glibenclamide → Mild hypoglycemia rate
Xiaoke Pill combined with Glibenclamide → Mild hypoglycemia rate
Xiaoke Pill combined with Glibenclamide → Total hypoglycemia rate
Xiaoke Pill combined with Glibenclamide → Total hypoglycemia rate
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Sulfonylureas and Achievement of HbA1c ≤ 6.5%, Sulfonylureas and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Achievement of HbA1c ≤ 6.5%
Measures Achievement of HbA1c ≤ 6.5% as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Sulfonylureas
Contributes to Sulfonylureas evidence base.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Sulfonylureas may lower HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Xiaoke Pill combined with Glibenclamide appears to improve achievement of HbA1c ≤ 6.5%.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Achievement of HbA1c ≤ 6.5%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Xiaoke Pill combined with Glibenclamide appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Xiaoke Pill combined with Glibenclamide appears to affect mild hypoglycemia rate.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Mild hypoglycemia rate
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
